UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
--------------
Date of Report (Date of earliest event reported): February 28, 2002
OXIGENE, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-21990 13-3679168
-------------- ----------- ------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
321 Arsenal Street
Watertown, Massachusetts 02472
------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 673-7800
Item 5. Other Events and Regulation FD Disclosure.
On February 28, 2002, the Registrant issued a press release announcing that the
Arcus Therapeutics LLC joint venture with Peregrine Pharmaceuticals Inc.
("Peregrine") will end with Peregrine paying the Registrant $2 million. Both
companies will reacquire full rights to their respective vascular targeting
technologies. The rights to any discoveries during the term of the agreement
will revert to Peregrine. A copy of the press release is attached hereto as
Exhibit 99.1,
Item 7. Financial Statements and Exhibits.
(c) The following exhibits are filed with this report:
Exhibit Number Description
- -------------- -----------
99.1 Press release of Registrant dated February 28, 2002.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
OXIGNENE, INC.
(Registrant)
Date: March 4, 2002 By: /s/ Frederick Driscoll
-----------------------
Name: Frederick Driscoll
Title: President of Operations
and Finance
3
EXHIBIT INDEX
Exhibit Number Description
- -------------- -----------
99.1 Press release of Registrant dated February 28, 2002.
4